Literature DB >> 10779762

Breakdown of tolerance to a neo-self antigen in double transgenic mice in which B cells present the antigen.

A F de Vos1, A Fukushima, M C Lobanoff, B P Vistica, J C Lai, J C Grivel, E F Wawrousek, S M Whitcup, I Gery.   

Abstract

Transgenic (Tg) mice expressing a foreign Ag, hen egg lysozyme (HEL), under control of the alphaA-crystallin promoter ("HEL-Tg" mice) develop immunotolerance to HEL attributed to the expression of HEL in their thymus. In this paper we analyzed the immune response in double (Dbl)-Tg mice generated by mating the HEL-Tg mice with Tg mice that express HEL Abs on their B cells ("Ig-Tg" mice). The B cell compartment of the Dbl-Tg mice was unaffected by the HEL presence and was essentially identical to that of the Ig-Tg mice. A partial breakdown of tolerance was seen in the T cell response to HEL of the Dbl-Tg mice, i.e., their lymphocyte proliferative response against HEL was remarkably higher than that of the HEL-Tg mice. T-lymphocytes of both Dbl-Tg and Ig-Tg mice responded to HEL at concentrations drastically lower than those found stimulatory to lymphocytes of the wild-type controls. Cell mixing experiments demonstrated that 1) the lymphocyte response against low concentrations of HEL is due to the exceedingly efficient Ag presenting capacity of the Ab expressing B cells and 2) breakdown of tolerance in Dbl-Tg mice can also be attributed to the APC capacity of B cells, that sensitize in vivo and stimulate in vitro populations of T cells with low affinity toward HEL, assumed to be escapees of thymic deletion. These results thus indicate that T cell tolerance can be partially overcome by the highly potent Ag presenting capacity of Ab expressing B cells.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10779762     DOI: 10.4049/jimmunol.164.9.4594

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  4 in total

Review 1.  Maintenance and loss of self-tolerance in B cells.

Authors:  A Iglesias
Journal:  Springer Semin Immunopathol       Date:  2001-12

2.  A novel inflammatory eye disease induced by lymphocytes from knockout mice sensitized against the deleted ocular antigen.

Authors:  M P Gelderman; P Charukamnoetkanok; J P Brady; L Hung; J S Zigler; E F Wawrousek; B P Vistica; E Fortin; C-C Chan; I Gery
Journal:  Clin Exp Immunol       Date:  2003-08       Impact factor: 4.330

3.  Inhibition of experimental autoimmune uveitis by amino acid copolymers.

Authors:  Hongen Yin; Barbara P Vistica; Chi-Chao Chan; Jack L Strominger; Igal Gery
Journal:  J Neuroimmunol       Date:  2009-09-11       Impact factor: 3.478

4.  Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus.

Authors:  Thomas Dörner; Joerg Kaufmann; William A Wegener; Nick Teoh; David M Goldenberg; Gerd R Burmester
Journal:  Arthritis Res Ther       Date:  2006-04-21       Impact factor: 5.156

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.